Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry.

David Dobarro,Víctor Donoso-Trenado,Eduard Solé-González, Carlos Moliner-Abós,José Manuel Garcia-Pinilla,Silvia Lopez-Fernandez,Sonia Ruiz-Bustillo,Carles Diez-Lopez,Javier Castrodeza, Ana B Méndez-Fernández, David Vaqueriza-Cubillo,Marta Cobo-Marcos,Javier Tobar, Igor Sagasti-Aboitiz, Miguel Rodriguez, Vanessa Escolar,Ana Abecia,Pau Codina,Inés Gómez-Otero,Francisco Pastor, Raquel Marzoa-Rivas,Eva González-Babarro,Javier de Juan-Baguda,María Melendo-Viu,Fernando de Frutos,José Gonzalez-Costello

ESC heart failure（2023）

引用 4|浏览4

暂无评分

摘要

In this large real-life series of AHF patients treated with levosimendan as destination therapy, we show a significant decrease of heart failure events during the year after the first administration. The simple LEVO-D Score could be of help when deciding about futile therapy in this population.

查看译文

关键词

Advanced heart failure,Inotropes,Levosimendan,Palliative care

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要